Cardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Diabete Mellitus. Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Elevated Cardiovascular Risk Scores With Diabetes Mellitus Type 2 and Their Association With Non-Invasive Visceral Adiposity Indices
Overview
calculate cardiovascular risk scores in type 2 DM patients, then estimate its association with new visceral adipose tissue indices
Detailed description
Cardiovascular disease (CVD) constitutes a significant health challenge for individuals with type 2 diabetes mellitus (T2DM), affecting approximately 32% of this population and contributing significantly to global mortality.Visceral adipose tissue (VAT) accumulation has been recognized as a major contributor to adverse cardiac remodelling. Unlike subcutaneous adipose tissue (SAT), VAT is metabolically active, promoting a pro-inflammatory, lipotoxic, and insulin-resistant environment that accelerates myocardial fibrosis, hypertrophy, and diastolic dysfunction. Despite its clinical significance, VAT is challenging to measure in routine practice. Advanced imaging modalities such as magnetic resonance imaging provide direct VAT assessment but it's costly, time-consuming, and impractical for large-scale screening. In contrast, traditional anthropometric measures like body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) do not distinguish VAT from SAT and fail to capture the true cardiometabolic burden of visceral fat .To address these limitations, researchers have focused on developing non-invasive visceral obesity indices that combine anthropometric and laboratory-based parameters. These indices are particularly relevant for T2DM patients, as insulin resistance often occurs when fat accumulates in intra-abdominal depots and is associated with a constellation of CVD risk factors, in what is known as the metabolic syndrome.
Primary outcome measures
- The prevalence of elevated 10-year cardiovascular risk scores among patients with type 2 diabetes mellitus. [Time frame: 1 YEAR]
Secondary outcome measures (1)
- The correlation between cardiovascular risk scores and non-invasive visceral adiposity indices (such as LAP and VAI). [Time frame: 1 YEAR]
Eligibility criteria
Inclusion criteria
- Adult patients ≥40 years old attending the out patients clinics
- Patients diagnosed with type 2 diabetes mellitus
Exclusion criteria
- Patient with a history of cardiovascular events
- Patient with type 1 diabetes or gestational diabetes.
- Pregnant women.
- Hypothyroidism,
- Cushing disease
- polycystic ovarian syndrome.
- Congestive heart failure
- chronic liver disease
.- chronic kidney disease,
- cancer
- Current use of steroids, birth control pills, antipsychotics, antidepressants, epilepsy drugs.
- Patients with physical deformities or conditions affecting anthropometric measurements.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Assiut university — Asyut
Publications
- Tawfik MY, Mohamed SF, Elotla SF. Association of novel visceral obesity indices with 10-year risk of major cardiovascular events in patients with type 2 diabetes mellitus. J Egypt Public Health Assoc. 2025 May 30;100(1):12. doi: 10.1186/s42506-025-00188-w. PMID 40445502
- Wang L, Liu S, Ke J, Cao B, Wang D, Zhao Q, Gong H, Fang Y, Zheng Z, Yu C, Wu N, Ma Y, Yu K, Yang L, Zhao D. Association between metabolic visceral fat score and left ventricular hypertrophy in individuals with type 2 diabetes. Diabetol Metab Syndr. 2025 Mar 6;17(1):81. doi: 10.1186/s13098-025-01648-1. PMID 40050939
- Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6. PMID 29884191
Identifiers
NCT: NCT07204782 · Visceral adiposity indices